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Background: The aim of this study was to perform a longitudinal assessment using Quantitative Muscle Testing
(QMT) in a cohort of ambulant boys affected by Duchenne muscular dystrophy (DMD) and to correlate the results
of QMT with functional measures. This study is to date the most thorough long-term evaluation of QMT in a cohort
of DMD patients correlated with other measures, such as the North Star Ambulatory Assessment (NSAA) or thee
6-min walk test (6MWT).
Methods: This is a single centre, prospective, non-randomised, study assessing QMT using the Kin ComW 125
machine in a study cohort of 28 ambulant DMD boys, aged 5 to 12 years. This cohort was assessed longitudinally
over a 12 months period of time with 3 monthly assessments for QMT and with assessment of functional abilities,
using the NSAA and the 6MWT at baseline and at 12 months only. QMT was also used in a control group of 13
healthy age-matched boys examined at baseline and at 12 months.
Results: There was an increase in QMT over 12 months in boys below the age of 7.5 years while in boys above the
age of 7.5 years, QMT showed a significant decrease. All the average one-year changes were significantly different
than those experienced by healthy controls. We also found a good correlation between quantitative tests and the
other measures that was more obvious in the stronger children.
Conclusion: Our longitudinal data using QMT in a cohort of DMD patients suggest that this could be used as an
additional tool to monitor changes, providing additional information on segmental strength.Background
Duchenne Muscular Dystrophy (DMD) is an X-linked
recessive disorder and is the most common muscular
dystrophy in children [1-6] The increasing number of
possible therapeutic strategies ready to enter in phase 2
or 3 clinical trials has highlighted the need for reliable
and reproducible outcomes measures. There has also
been increasing evidence of the need to collect natural* Correspondence: yvan.torrente@unimi.it
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reproduction in any medium, provided the orhistory data in order to establish the rate of progression
and the variability of muscle strength and functional
changes in a disease that does not have a linear progres-
sion with increasing age. The North Star Ambulatory
Assessment (NSAA) and the 6 min walking test
(6MWT), a measure previously used in other disorders,
have been recently proposed as possible measures for
ambulant DMD [7-9] The choice of this measures reflect
the need for assessing aspects of function that are clinic-
ally meaningful for patients. In a research setting, how-
ever, the trial design may also need objective and
sensitive measures of individual muscles, as opposed to
functional scales that often measure movements involv-
ing many muscles in different muscle groups. The QMT
(Quantitative Muscle Testing) is a sensitive tool toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing to test specific muscle groups [10-20]. And to moni-
tor the response to treatment of individual muscles or
groups of muscles [11,12,16]. Reliability of strength test-
ing with QMT has already been established in healthy
controls [13-15,21], and QMT, assessed using the Kin
ComW dynamometer, has also already been used in
DMD boys in studies on myoblast transplant [11,12].
The aim of our single centre, prospective, non-rando-
mised, study was i) to provide a longitudinal assessment
of quantitative muscle strength over one year in a cohort
of ambulant DMD boys, ii) to assess possible differences
with a small cohort of age- matched male controls and
iii) to establish its correlation with other measures such
as functional scales and 6MWT .
Methods
Study population
28 DMD patients were selected on the basis of a con-
firmed DMD diagnosis (i.e. clinical features, serum cre-
atine kinase, muscle biopsy and genetic analysis), age
between 5 and 12 years, ability to ambulate at the time
of selection, absence of severe cardiac and pulmonary
disease. Median age was 8.5 years (range 5–12). All had
a diagnosis of DMD with clinical findings consistent
with DMD, absence of dystrophin on muscle biopsy con-
firmed by genetic analysis. All but two were on steroids
with a median prednisolone adjusted dose of 11.5 mg/
kg/month (range 7.5-24). Steroid dosage was not chan-
ged during the study but weight adjustment was applied.
None of the subjects had health problems other than
DMD. Vital signs such as oxygen saturation, respiratory
frequency, body temperature and diastolic blood pres-
sure were normal for age. Neurological examination at
the time of selection showed anserin ambulation in 25/
28 patients and reduced tendon reflexes in 25/28
patients. No one had severe scoliosis or severe contrac-
tures that could have limited the use the assessment of
strength. Serum chemistry evidenced a median serum
creatine kinase of 6408 (range: 3204–26353), AST of 226
U/L (range: 89–629) and ALT of 345 U/L (range 113–
702). Baseline cardiological examination, ECG and echo
were normal respectively in 28 (100%), 24 (86%), 26
(89%) subjects. 4 subjects showed right bundle branch
block and 2 respectively minimal mitral valve insuffi-
ciency and posterior wall hypertrophy of no clinical rele-
vance. Pulmonary function tests were evaluable in 25
subjects, normal in 20 subjects while 5 subjects had
minimal respiratory insufficiency. This study was
approved by the ethical committee of the San Raffaele
hospital of Milan (Italy)(reference number DMD01). Par-
ents of all included affected and non-affected boys
agreed and signed a written informed consent for the
participation in the study.Functional and quantitative muscle assessment
The study cohort was assessed at three month intervals
for one year for QMT and at baseline at 12 months for a
more comprehensive assessment, also using the NSAA
and 6MWT. The control group only performed quanti-
tative muscle test assessment at baseline at 12 months.
Quantitative assessment
Two examiners performed the evaluation using the Kin
ComW Robotic Dynamometer (Chattanooga Group Inc.,
Chattanooga, TN, USA) The muscle groups tested with
Kin ComW were knee extensor and flexor, through iso-
metric and isokinetic protocol and elbow extensor and
flexor, through isometric protocol. During both lower
and upper limb evaluation, subjects seated on the chair
of a dynamometer. The seat was adjusted to the size of
the boy. A seat belt around the hips and two around the
trunk were used to maintain proper position during test-
ing, to isolate the single joint test (knee or elbow) by lim-
iting patient compensatory movements patient during
exercise. The boy was asked to keep his arms folded
across his chest. The evaluator aligned the axis of the
dynamometer to the articular axis of the tested joint
(knee or elbow). The lever arm length was adjusted in
proportion to the length of the leg (the pad was placed
proximal to the ankle joint). During isometric tests knee
and elbow joint were positioned at 90°, measured with a
goniometer, while during knee isokinetic test the range of
motion varied from 90° to 10°. The DMD boy watched
the computer screen for visual-feedback during the con-
traction. The evaluation was divided in two session: the
first regarding lower limb lasting 40 min and a second
session for the upper limb evaluation which took ap-
proximately 15 min. Between sessions patients had at
least 30 min of rest while they could come back to their
parents. Subjects were asked to perform three times each
exercise with a maximum contraction, kept for five sec-
onds. During evaluation the subject was asked to pull or
push as hard as he could and the same evaluator gave, for
each test, the same continuous verbal encouragements.
Functional assessment
NSAA
This scale, specifically designed for ambulant DMD boys
(see Additional file 1: Table S1 in the supplementary in-
formation) consists of 17 items, ranging from standing
(item 1) to running (item 17) and includes several items
assessing abilities that are necessary to remain function-
ally ambulant, items assessing abilities, such as head
raise and standing on heels that can be partly present in
the early stages of the disease and a number of activities
such as hopping, or running that are generally never
fully achieved in untreated DMD boys but that have
been found in those treated with daily steroids.
Lerario et al. BMC Neurology 2012, 12:91 Page 3 of 8
http://www.biomedcentral.com/1471-2377/12/91Each item can be scored on a 3 point scale using sim-
ple criteria: 2 -Normal achieves goal without any assist-
ance; 1 -Modified method but achieves goal independent
of physical assistance from another person; 0 - Unable
to achieve independently.
A total score can be achieved by summing the scores
for all the individual items. The score can range from 0,
if all the activities are failed, to 34, if all the activities are
achieved. The scale is generally completed in a max-
imum of 15 min. The NSAA also includes the possibility
to record timed items (10 m timed walk/run test and
time to rise from the floor or Gower test) [12,13,22].
6MWT
The 6MWT was performed using a modified version of
the American Thoracic Society (ATS) guidelines for the
test [7,23]. Modifications include the addition of a short
orientation video prior to testing, continuous encourage-
ment from the testing staff, and a “safety chaser” to walk
along behind the subject during testing. The test is gen-
erally completed within 15 to 20 min, including the
instructions. The assessments were performed by exami-
ners specifically trained on this measures. Videotaping
of both assessments was recorded after consent was
obtained. During 6-min walking test patients were asked
to walk steadily and quickly, without running, along a
distance of 15 m. Encouragement was given during the
assessment, and DMD boys were informed each minute
of the time remaining. Patients were allowed to stop, if
necessary, and start again within the 6 min.
Statistical analysis
Kin ComW measurements were evaluated cross-
sectionally and longitudinally over a 12 months period
of time with 3 monthly assessments. Left and right mea-
surements were averaged and the mean value was used
for all the analyses. Differences between baseline values
and those measured after one year between patients and
control subjects were compared by an ANOVA model,
adjusting for age. In the patients’ group, the dependence
of the baseline values with age was preliminarily assessed
by a visual inspection of the plots and non-linear rela-
tionships with age were analysed using a piecewise linear
regression. A piecewise regression model allows for
changes in slope and consists of two or more straight
line segments. Models with one point of slope change
were fitted. The time trend of the Kin ComW measures
over one year was assessed using a mixed effect linear
model accounting for the within-subjects correlations,
with a time x age interaction term, evaluating whether
the slope of change is different across ages. Different age
cut off points were used to categorize age in the inter-
action analysis (as above and below the cut off point).
Correlations between baseline values and longitudinalslopes were evaluated using a Spearman rank correlation
coefficient. The quantification of the random fluctua-
tions of the Kin ComW variables of an untreated popula-
tion is important to understand whether a change over
time in a clinical trial can be considered within fluctua-
tions that can be expected by chance or it’s large enough
to be considered due to a treatment effect. Therefore the
Kin ComW variations at three months intervals were
studied: a regression line was fitted for each patient and
a linear trend of the Kin ComW variables over time was
estimated. An analysis of the residuals (distances of the
observed values from the predicted regression lines) was
used to estimate the magnitude of the random fluctua-
tions of each Kin ComW variable. Random fluctuations
were defined as those within the 95% Confidence Inter-
vals of the distributions of residuals. All the statistical




The baseline characteristics of the studied population
are reported in Table 1. The average age is 8.3 years
(SD= 2.3), with 8 subjects in the range 5–7, 13 subjects
in the range 7–9 and 7 subjects in the range 9–12.
Baseline values
Average baseline values of the functional scales and Kin
ComW measures for patients and healthy controls are
reported in Table 1. All the Kin ComW measurements
were significantly lower in patients than in controls. The
relationships of the patients’ measurements with age
were analysed by a linear model and by a piecewise lin-
ear regression model with one point of slope change.
The piecewise regression model resulted better fitting
the relationships between all the baseline values of the
functional scales than a simple linear regression model
(Figure 1). The results of the piecewise regression ana-
lysis are reported in Additional file 1: Table S1 for all the
Kin ComW measures the point of slope change was
around 8.5 years. The coefficients reported in Additional
file 1: Table S1 indicate an increase with age when posi-
tive and a decrease with age when negative: for example,
before the age of 8.8 years isometric KF was the meas-
urement with the highest increase with age (+9 points
per year, p = 0.017) while after the age of 8.8 years it
showed significant decrease of −15.7 points per year
(p = 0.0015, Figure 1).
Baseline correlations
Table 2 reports the correlations between baseline values
of 6MWT, NSAA and the Kin ComW measures. All the
baseline Kin ComW measures values highly correlate
with all the other measures. Correlation of the baseline
Table 1 Baseline characteristics of the enrolled population
Patients N= 28 Controls N= 13 P value
Mean (SD) Median (range)
Age 8.4 (1.6) 8.5 (5.6-12.0) 9.5 (2.8) 10.5 (5.5-12.5) 0.11
NS 24.2 (8.5) 27.5 (4–34) - -
6MWT (m) 361.2 (98.0) 386 (42–518) - -
10 M (s) 6.8 (6.3) 5.1 (3–36) - -
GOWERS (s) 8.0 (9.5) 4.7 (1–45) - -
Isometric KE (N) 56 (35) 53 (10–134) 310 (151) 251 (135–628.3) <0.01*
Isometric KF (N) 52 (20) 51 (14–93) 130 (55) 124 (60–225) <0.01*
Isocinetic KE (N) 59 (33) 51 (15–141) 276 (128) 260 (130–546) <0.01*
Isocinetic KF (N) 48 (20) 49 (10–100) 124 (46) 122 (59–223) <0.01*
EE (N) 26 (14) 24 (5–56) 101 (49) 94 (25–168) <0.01*
EF (N) 24 (10) 22 (7–46) 113 (57) 100 (55–225) <0.01*
*p values adjusted for age.
Abbreviations: NS = North Star Scale; 6MWT = 6-min walking test; KE = Knee Extension; KF = Knee Flexion; EE = Elbow Extension; EF = Elbow Flexion.
Figure 1 Baseline values of the Kin ComW measures are plotted against patients age. The fitted lines represent the linear dependency of
these values with age, with one point of slope change, that was estimated by a piece-wise regression.
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6MWT (m) r 0.80 1
p <0.001
TIME10m (s) r −0.93 −0.80 1
p <0.001 <0.001
Gowers (s) r −0.89 −0.75 0.91 1
p <0.001 <0.001 <0.001
Isometric KE (N) r 0.86 0.70 −0.89 −0.87 1
p <0.001 <0.001 0.01 <0.001
Isometric KF (N) r 0.66 0.60 −0.64 −0.52 0.50 1
p <0.001 <0.001 <0.001 0.007 <0.001
Isocinetic KE (N) r 0.87 0.72 −0.86 −0.88 0.93 0.64 1
p <0.001 <0.001 0.01 <0.001 <0.001 <0.001
Isocinetic KF (N) r 0.64 0.63 −0.68 −0.66 0.62 0.73 0.70 1
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
EF (N) r 0.63 0.68 −0.65 −0.63 0.63 0.52 0.55 0.59 1
p <0.001 <0.001 .01 0.001 <0.001 <0.001 <0.001 <0.001
EE (N) r 0.75 0.59 −0.84 −0.77 0.75 0.55 0.73 0.65 0.76
p <0.001 <0.001 0.01 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Abbreviations: r = Pearson correlation coefficient, NS = North Star Scale; 6MWT = 6-min walking test; KE = Knee Extension; KF = Knee Flexion; EE = Elbow
Extension; EF = Elbow Flexion.
Lerario et al. BMC Neurology 2012, 12:91 Page 5 of 8
http://www.biomedcentral.com/1471-2377/12/91Kin ComW values with the baseline NS scores is shown
in Figure 2.Longitudinal assessment
Additional file 2: Table S2 reports the one-year changes
of all the Kin ComW measurements in patients and inFigure 2 Correlations between all the Kin ComW measures with
the North Star functional scale at baseline. Each symbol
represent a different Kin ComW variable: Black dot: Isometric Knee
Extension, White dot: Isometric Knee Flexion, Black square: Isocinetic
Knee Extension, White square: Isocinetic Knee Flexion, Black triangle:
Elbow Extension, White triangle: Elbow Flexion.healthy controls. All the average one-year changes of
patients were significantly lower than those experienced
by healthy controls (Additional file 2: Table S2), who
showed as expected a progressive improve. Additional
file 3: Table S3 reports the results of the longitudinal
analysis in the patients group. As for baseline values,
most of the longitudinal changes (excluding EE and EF)
of the Kin ComW measurements depend on age; this is
represented by a significant age x time interaction in
Additional file 3: Table S3. For Kin ComW measures with
a time trend significantly different at different ages (age x
time interaction), the slope (representing the average
change for a three months interval) is reported separately
for children above and below the age of 7.5 years. This
value resulted as the cut off better discriminating one-
year changes in this population. This is lower than the
value of 8.5 years that was estimated by the cross-
sectional analysis; however, the small sample of patients
used in this analysis justifies a certain degree of variabil-
ity in detecting the age of slope change when analyzed
with different approaches. On the average, all the Kin
ComW measures increase their value over the 12 months
of observation in children below the age of 7.5 years: iso-
metric KE has a 3 monthly significant increase of 2.4
points (SE = 0.8, p < 0.001) and isometric KF of 1.0 point
(SE = 0.3, p = 0.002). Isokinetic KE and KF also increased
in children below 7.5 years, but this change was not
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crease over time for the whole cohort of children (+1.2
(SE = 0.1) and +0.6 (SE = 0.1) points every 3 months,
p < 0.001 for both).
In children above the age of 7.5 years, isometric KE,
isokinetic KE and isokinetic KF showed a significant de-
crease (−0.4 (SE = 0.2), -0.4 (SE = 0.2), and −0.6 (SE = 0.2)
points every 3 months, p = 0.04, p = 0.04 and p < 0.001
respectively). All the average one-year changes were sig-
nificantly different than those experienced by healthy
controls (Additional file 2: Table S2).
Correlations of longitudinal changes
In Additional file 3: Table S3 the correlations between
the one-year change, expressed as a 3 monthly slope, of
Kin ComW measures and functional scales are reported.
The 3 monthly change (Figure 3) of the isometric KE
values correlated with the change of the NS values
(r = 0.32, p = 0.09) and of the GOWERS values (r =−0.40,
p = 0.04); the 3 monthly change of the isometric KF cor-
related with the change of the 6MWT (r = 0.50, p = 0.01)
and the change of the 10 m time (r =−0.47, p = 0.01); the
3 monthly change of the isokinetic KF correlated with
the change of the 6MTW (r = 0.51, p = 0.01) (Figure 3).
Estimation of random fluctuations over time
In order to estimate the random fluctuations of the Kin
ComW values, the residuals around the linear trend over
time for each patient were examined (Additional file 4:
Table S4). A regression line was estimated for each pa-
tient according to the 3-monthly spaced time points
(months 0-3-6-9-12) and the deviations from these re-
gression lines were estimated and mediated over all the
patients. As reported in Additional file 4: Table S4, if a
slope is estimated for a patient, deviations between theFigure 3 The 3 monthly change of and isocinetic KF is plotted
against the 3 monthly change of the 6MWT.9% and the 17% of the baseline value can be observed.
In absolute terms, deviations of 12.5 N for Isometric KE,
of 9.6 N for Isometric KF, of 10.2 N for Isocinetic KE
and Isocinetic KF, of 7.8 N for EE and of 6.9 N for EK
can be considered random fluctuations around each
patient’s slopes.
Discussion
In the last few years there have been large international
efforts in order to identify outcome measures in DMD.
The course of DMD is actually measured by serial clin-
ical assessments of muscle strength, pulmonary function,
and functional rating scales. A number of measures in-
cluding the 6MWT and different timed items or func-
tional scales have been proposed for ambulant DMD
patients as part of safety studies or in early stages of
treatment. These measures rely on patient effort or on
subjective rating of function. However some treatments
may be administered to specific groups of muscles, and
we therefore need additional measures that may detect
and monitor minimal changes in a single muscle or in
muscle groups. For these reasons, quantitative assesment
have been explored as adjuncts to the physical examin-
ation in the assessment of patients with neuromuscular
disorders. In this study we assessed QMT using the Kin
ComW, an assessment already used in DMD boys in pre-
vious studies and with pediatric normative data. The
results of our study show that this technique can be reli-
ably used in DMD boys and that can assess changes over
time. All our DMD boys were able to understand
instructions to perform the quantitative assessments,
showing good participation and motivation. Further-
more, although two patients lost ambulation in the
course of the year and thus were unable to continue to
perform functional measures, all patients completed the
assessment with the Kin ComW dynamometer. Having
five time points (3 monthly spaced assessments over one
year) we were also able to estimate a linear trend with
time for each Kin ComW variable. The deviations from
these trends represent the normal random fluctuations
that can be expected in a population of DMD patients
[22,24-29]. It is of interest that the results of both cross
sectional and longitudinal assessment showed that the
slope of deterioration in DMD boys occurs at approxi-
mately 7.5 years. These results are in agreement with
our recent observation obtained in a multicentric study
and in a much larger cohort using 6MWT and NSAA.
Not surprisingly, the decline was more obvious after the
age of 9, in all quantitative tests performed with the Kin
ComW dynamometer during right and left isometric and
isokinetic flexion/extension of the knee and during iso-
metric flexion/extension of the elbow. The strength
value of lower and upper limbs obtained with Kin ComW
show no significant difference between right and left
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the average one-year changes were significantly different
than those experienced by the age matched controls. In
order to have a more complete assessment, at baseline
and 12 months the study cohort was also assessed using
the NSSA and the 6MWT. There was a high degree of
correlation between the functional tests and isokinetic
knee extension tests, especially for correlation between
isokinetic knee tests and value of North Star scale.
The results obtained indicate that the use of QMT, in
addition to the functional scales, provides sensitive and
objective information of muscle strength changes of
DMD patients, suggesting that the Kin ComW dynamom-
eter is a valid, sensible and reproducible tool to evaluate
muscle strength in ambulant and allowed us to have
some results also in patients who lost ambulation
after baseline. Therefore, the combination of isometric/
isocinetic QMT and functional measures should be
regarded as a useful outcome measure for clinical trials
in which the mechanism of the drug is expected to pro-
duce an increase in strength. Although the numbers were
relatively small, our findings information expand the
spectrum of our knowledge on individual measures but
also provides more insights on their correlation as quan-
titative muscle strength assessments, 6MWT and func-
tional measures have all been previously investigated in
DMD but had never been assessed in the same cohort.Conclusion
Prospective, longitudinal multicenter studies are needed
to assess the relative sensitivity of isometric/isocinetic
QMT to measure changes in DMD disease pathology as
compared to functional strength outcome measures and
for detecting the effects of future treatments. Depending
on the design of the trial, the combination of functional
measures and Kin ComW dynamometer assessment may
offer a more complete and sensitive method of outcome
measures when objective measures of strength are
needed.Previous presentation
Presented as oral communication at 39th European
Muscle Conference of the European Society for Muscle
Research. Abano Terme, Padova, Italy, September
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